echinococcosis
Conditions
Interventions
Group A:emulsion albendazole
Group B:Albendazole tablets
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 14-70 years old, M (male) or F (female), no district on ethnic group; 2. Random before meeting the following diagnostic standards: A. Imaging of abdominal B ultrasound or CT confirmed; B. Imaging (B-mode ultrasonography) diagnosed with single cyst (CE1) or multiple cyst (CE2), or internal collapse necrosis (CE3) hydatid cysts, maximum diameter less than 8cm (including 8cm); C. Rapid diagnostic kit can be used as auxiliary diagnostic criteria confirmed hydatid. 3. Patients with hepaitc cystic echinococcosis who want be volunteer and accept consecutive maedical treatment at least 12 months; 4. Unwilling to operation or multiple operation to take medication for the recurrence of hepatic cystic echinococcosis; 5. According to the GCP and local regulations, visiting 1 informed consent was signed and dated.
Exclusion criteria
Exclusion criteria: 1. Cystic echinococcosis necrosis of consolidation or completely calcified (CE4 and CE5) and various types of alveolar echinococcosis; 2. Patients with severe single organ or multiple organ function damage; 3. Pregnant and lactating women; 4. Unwilling to accept drug treatment; 5. Patients with abnormal liver function: ALT or AST or bilirubin is 3 times higher than the upper treshold of the normal value; 6. Patients with renal dysfunction: serum creatinine is 2 times higher than the upper limit of the normal value, or urinary protein positive; 7. Allergic constitution and had the history of drug allergy; 8. Need to accept the treatment of other may have effects on liver and kidney function and bone marrow hematopoietic during test; 9. Any researchers think tips may increase the subjects of danger or interference test result or product instructions; 10. Signed informed consent before 3 months, had alcohol or drug abuse, the researchers estimate will affect the test involved, or the presence of any condition causing compliance to study procedures or study drug decline; 11. In signing the informed consent before 30 days, the test was involved in another test of drug; 12. In the clinical trials, any may endanger patient safety to other clinical conditions (the researchers estimate).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| general effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| cure rate;effective rate; | — |
Countries
China
Contacts
Public ContactWen Hao
First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed